Medicxi
Medicxi is a London-based life sciences venture capital firm founded in 2016, managing over €1.8 billion across early- and late-stage biotech funds using an asset-centric investment model. It serves biotech entrepreneurs in Europe and has executed 32 exits including Vicebio ($1.6B) and Micromet.
- Company typePrivate
- Founded2016
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Medicxi does
Medicxi is a London-headquartered venture capital firm specializing in European life sciences investing, founded in 2016 when the life sciences team spun out of Index Ventures. The firm pioneered the 'asset-centric' investment model, which concentrates capital and resources on single-molecule or single-asset biotech companies structured as virtual operations, in contrast to traditional multi-asset biotech platforms. Medicxi manages a series of complementary funds spanning the development continuum: early-stage vehicles (Medicxi Ventures 1 / MV1, Medicxi III, Medicxi IV, Fund V) and the late-stage Medicxi Growth 1 (MG1), with cumulative fundraising exceeding €1.8 billion and the most recent Fund V closing at €500 million in November 2025.
The firm's portfolio spans 91 biotech companies across modalities and therapeutic areas, with 32 realized exits to date including Genmab, Micromet (acquired by Amgen), Molecular Partners, and recent 2025-2026 transactions such as Vicebio (acquired by Sanofi for up to $1.6 billion), Curevo and Centessa Pharmaceuticals (acquired by Eli Lilly), and RAPT Therapeutics (acquired by GSK). Cornerstone limited partners include major pharmaceutical companies—GSK, Novartis, Johnson & Johnson Innovation-JJDC, and Verily (Alphabet)—alongside the European Investment Fund, providing both capital and scientific advisory support. The leadership team includes co-founders Francesco De Rubertis, David Grainger, Kevin Johnson, and Michèle Ollier, augmented by Partner Moncef Slaoui (former GSK Chairman of Pharmaceutical R&D) and Venture Partners Sandy Zweifach and Paul Sekhri.
Medicxi generates revenue through conventional fund management economics—recurring management fees on committed and deployed capital across its fund vintages, plus carried interest on realized exits. The firm identifies and backs biotech entrepreneurs and drug hunters through direct scientific networks, industry conferences, and pharma partnerships, with offices in London, Geneva, and St Helier (Jersey). Its core differentiation is the asset-centric thesis: by isolating single assets in focused capital structures, Medicxi argues it achieves superior capital efficiency, faster decision-making, and clearer exit pathways versus traditional biotech venture models.
Medicxi firmographics
Firmographics- Name
- Medicxi
- Legal name
- Medicxi Ventures (UK) LLP
- Website
- https://medicxi.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medicxi is a London-based life sciences venture capital firm founded in 2016, managing over €1.8 billion across early- and late-stage biotech funds using an asset-centric investment model. It serves biotech entrepreneurs in Europe and has executed 32 exits including Vicebio ($1.6B) and Micromet.
- Ownership category
- akta.pro rank
Medicxi industry classification
Industry- Product category
- Venture Capital — Life Sciences Investment
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Medicxi is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Medicxi business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Fund Management: Generates revenue through management fees and carried interest from venture funds focused on life sciences investments.
Go-to-market motion1 record
Marketing channels4 records
Medicxi product offering
Product offeringCore offering
Medicxi is a European life sciences venture capital firm that manages multiple dedicated investment funds spanning early-stage to late-stage biotech investments. The firm employs an asset-centric investment model, backing single-asset virtual biotech companies to maximize capital efficiency in drug development across discovery, clinical proof-of-concept, and late-stage regulatory phases.
Product overview
Medicxi is a European life sciences venture capital firm offering an integrated platform of investment funds spanning early-stage to late-stage biotech investments. The firm manages multiple dedicated life sciences funds: Medicxi Ventures 1 (MV1) at €210 million for early-stage investments, Medicxi Growth 1 (MG1) at $300 million for late-stage companies with Phase II+ assets, Medicxi III at €400 million for discovery through late-stage assets, and Fund V at €500 million as its most recent oversubscribed fund. The firm employs an asset-centric investment model that focuses on virtual, single-asset companies to maximize capital efficiency in drug development.
Differentiator
Problem solved
Functional benefit
Brands
- Medicxi Growth 1 (MG1): Late-stage growth fund focused on European biotech companies with Phase II or beyond clinical assets
- Medicxi Ventures 1 (MV1)
Products and services
- Medicxi Ventures 1 (MV1) A €210 million early-stage venture fund that predominantly invests in European life sciences companies following the asset-centric strategy.
- Medicxi Growth 1 (MG1) A $300 million late-stage growth fund focused on European biotech companies with at least one asset in Phase II or beyond clinical development.
- Medicxi III Fund A €400 million fund that invests across the full healthcare continuum from discovery to late-stage clinical assets, supporting scientific entrepreneurs and drug hunters.
- Medicxi IV Fund A $400 million fund continuing the asset-centric biotech investment strategy.
- Medicxi Fund V A €500 million oversubscribed venture fund that continues the asset-centric investment strategy in biotechnology companies, supporting drug development across all development stages.
Companies that use Medicxi
Customer profileNamed customers8 records
Segments2 records
Ideal customer profiles3 records
Medicxi technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Medicxi partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Dr Moncef SlaouicoreFormer GSK Chairman of Pharmaceutical R&D and Vaccines. Joined as Partner in 2017, bringing extensive clinical and leadership experience. Also serves on Scientific Advisory Boards.
Scale indicators7 records
Recent moves10 records
Expansion highlights5 records
Medicxi competitors and assessment
Company assessmentDirect peers
- Atlas Venture: Atlas Venture is a Boston- and London-based venture firm focused on building early-stage biotech companies, often around single-asset platforms. Directly comparable to Medicxi in asset-centric philosophy, fund size, and European/US dual presence.
- Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds across early and late-stage biotech. Directly comparable to Medicxi in European life sciences focus, fund scale, and portfolio construction approach.
- Sofinnova Partners: Sofinnova is one of Europe's longest-standing life sciences venture capital firms, investing across therapeutic platforms with similar fund vintages. Comparable to Medicxi in European focus, life sciences specialization, and clinical-stage asset orientation.
- Novo Holdings (Novo Ventures): Novo Holdings' venture arm manages multi-billion life sciences investments with similar European and US life sciences mandate. Comparable to Medicxi in fund scale, biotech-only focus, and long-term horizon capital deployment.
- Abingworth: Abingworth is a transatlantic life sciences investment firm with early- and late-stage strategies. Directly comparable to Medicxi in clinical-stage European biotech investing and dual-fund (venture + growth) structure.
- OrbiMed: OrbiMed is a global healthcare-dedicated investment firm across private and public markets. Comparable to Medicxi in healthcare-only mandate and clinical-stage biotech investing, though much larger in AUM and broader in mandate.
- Index Ventures: Index Ventures is the predecessor firm from which Medicxi's life sciences team spun off in 2016, retaining shared operational heritage and life sciences investing DNA. Directly comparable as the originating firm with parallel life sciences strategy.
- Versant Ventures: Versant is a healthcare-focused venture firm building biotech companies across stages with Inception Sciences-style company creation. Comparable to Medicxi in clinical-stage biotech focus and company-building model.
- RA Capital Management: RA Capital is a Boston-based healthcare-focused investment firm with crossover and private strategies. Comparable to Medicxi in clinical-stage life sciences investing and use of structured deals around single assets.
- 5AM Ventures: 5AM Ventures is a US life sciences venture firm focused on early-stage biotech with company-creation expertise. Comparable to Medicxi in life sciences specialization, single-asset focus, and clinical development orientation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Medicxi social profiles
Digital presenceMedicxi financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medicxi leadership team
Management profileNumber of profiles
Profiles13 records
Medicxi funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medicxi M&A and investment
M&A and investmentM&A
Investments61 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medicxi
What does Medicxi do?
Medicxi is a European life sciences venture capital firm that manages multiple dedicated investment funds spanning early-stage to late-stage biotech investments. The firm employs an asset-centric investment model, backing single-asset virtual biotech companies to maximize capital efficiency in drug development across discovery, clinical proof-of-concept, and late-stage regulatory phases.
Is Medicxi a public or private company?
Medicxi is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Medicxi founded?
Medicxi was founded in 2016. It employs 11 to 50 people.
Where is Medicxi based?
Medicxi is headquartered in London, United Kingdom, in the Europe region.
How does Medicxi make money?
One revenue line is on record: fund Management.
Who are Medicxi's main competitors?
Direct peers on record are Atlas Venture, Forbion, Sofinnova Partners, Novo Holdings (Novo Ventures), Abingworth, OrbiMed, Index Ventures, Versant Ventures, RA Capital Management and 5AM Ventures.
Does Medicxi have an API?
No public API is recorded for Medicxi.
What industry is Medicxi in?
Medicxi's product category is Venture Capital — Life Sciences Investment. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 523940 and its SIC code is 6282.